Clinical Trial Search

Primary: Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted — 76.2; 41.4 minutes — p=0.0354

Primary: Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2 — 7.7; 11.7; 4.8 Minutes — p=<0.0001

Primary: Total Sleep Time in the First Two Thirds of the Night — 156.1; 216.4 Minutes — p=<.0001

Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours

Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018

Primary: Change From Baseline Time of Dim Light Melatonin Onset (DLMO) at 4 Weeks — -1.23; -1.58 Hours — p=0.510

Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours

Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)

Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884

Primary: Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) — 59.30; 39.40; 55.94; 55.12 minutes — p=0.646

Primary: To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log…

Primary: Change in School Night Sleep Onset Time — 0.4; 0.6 hours

Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants

Primary: Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI) — 11.56; 11.45; 9.52; 8.67 scores on a scale

Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1

Primary: Metabolic Syndrome Components — -2.7; 4.7 mmHg — p=0.013

Primary: Total Sleep Time — 382.9; 339.2; 256.2 minutes

Primary: Total Score on the Hamilton Rating Score for Depression (HRSD) - 21 Item Version — 19; 18.5; 10.2; 14.4 Total score on a scale — p=<0.05

Primary: 17-Item Hamilton Rating Scale for Depression Score (Independent Evaluator) — 8.66; 10.46 units on a scale

Primary: Retention Rate — 0; 1; 2 Participants

Primary: Severity of Depression as Measured by the Quick Inventory of Depressive Symptomatology (QIDS) Pre-Treatment — 10.8; 10.8 score on a scale

Primary: Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of Treatment — 76.34; 77.64; 78.45; 76.38…

Primary: Pittsburgh Sleep Quality Index — 7.0 units on a scale — p=0.37

Primary: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score — 72.64 units on a scale

Primary: Continuous Glucose Monitoring - Time in Range (70-140 mg/dl) — 36.3; 45.6; 37.2; 43.9 percentage of Time in Range 70-140mg/dL — p=<0.05

Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose

Primary: Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo — 58.88; 40.70; 32.27; 18.42 minutes (min) — p=0.908

Primary: Change From Baseline in the Average of the DSST RBANS Scores at the End of Each Double-blind Treatment Period — 6.49; 4.75 score on a scale — p=0.009

Primary: Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at…

Primary: TST — 5.7; 6.0 hours